The Children's Cancer Group (CCG) found that children with moderate risk acute lymphoblastic leukemia (ALL) had an improved 5-year event-free survival (EFS) rate when treated with therapy that included a doubled delayed intensification (DDI) vs a single DI (SDI) phase. Because of increased toxicity with DDI, it is important to determine whether subgroups of children with ALL can be identified who have excellent outcomes with SDI therapy. TEL-AML1 fusion and hyperdiploid DNA content are present in the leukemic blasts of significant proportions of children with ALL and have been associated with an excellent prognosis. In this study, we retrospectively examined the impact of TEL-AML1 status and ploidy on treatment outcome in a cohort of 75 children with standard risk ALL treated at our institution between 1983 and 1993 with SDI therapy. TEL-AML1 fusion was present in 19/43 (44%) evaluable cases. Fifteen of 56 (27%) evaluable cases were classified as hyperdiploid based on a modal chromosome number of у51 and/or a DNA index of у1.16. The 7-year EFS was 81% for the 19 TEL-AML1-positive patients vs 54% for the 24 TEL-AML1-negative patients (P = 0.0264). In multivariate analyses, TEL-AML1-positive status was associated with a superior EFS (P = 0.02) even when the intial white blood count was included in the model. Overall survival (OS) at 7 years for TEL-AML1-positive patients was 100% vs 83% for TEL-AML1-negative patients (P = 0.0677). There were no differences in 7-year EFS or OS based on ploidy comparisons. These results underscore the need to examine closely the effects of treatment intensification on specific biologically defined subgroups of children with ALL.
Introduction
Over the past three decades, identification of more effective drug combinations, improvements in supportive care, and treatment stratification based upon clinical and biological risk factors have contributed to substantial improvements in the cure of childhood acute lymphoblastic leukemia (ALL). With current therapeutic strategies, 75% of children with ALL are expected to be long-term survivors, and subgroups of patients can be identified that have long-term event-free survival (EFS) rates of 85% or greater. [1] [2] [3] Therefore, therapeutic strategies must attempt to balance the potentially competing goals of maximizing clinical efficacy and minimizing acute and chronic toxicity.
Treatment for childhood ALL typically includes several distinct phases: induction, intensification (consolidation), presymptomatic central nervous system therapy (CNS prophylaxis), and maintenance. One of the most commonly used intensification phases, termed delayed intensification (DI), was first introduced by the Berlin-Frankfurt-Mü nster (BFM) group in their 76/79 trial for ALL and produced improved disease-free survival rates in high risk patients. 4 The Children's Cancer Group (CCG) subsequently incorporated DI, with modest modifications, into their treatment strategies for children with ALL. The CCG 105 study demonstrated that addition of a single DI improved EFS from 61% to 73% in children with moderate risk ALL (defined in CCG 105 as age 12-23 months with white blood cell count (WBC) Ͻ50 000/mm 3 , age 24-119 months with WBC 10-50 000/mm 3 and age 120-251 months with WBC Ͻ50 000/mm 3 ). 5 Later, CCG 1891 randomized children with moderate risk ALL (defined in CCG 1891 as 2 Ͻ age Ͻ 10 years, WBC 10 000-49 999/mm 3 or age 1-Ͻ2 years, WBC Ͻ10 000/mm 3 to receive one (single DI or SDI) or two (double DI or DDI) DI phases and found that DDI significantly increased the 5-year EFS from 77% to 84%. 6 At the current time, DDI is being used by the CCG as standard therapy for children with standard risk (SR) ALL as defined by the NCI criteria (age 1-9.99 years, WBC Ͻ50 000/mm 3 ). 7 While the addition of a second DI was clearly efficacious in the overall population enrolled on CCG 1891, it is important to recall that it provided no added benefit for 93% of the children who received this intensification (77% who would be cured without it, and 16% who still were not cured with it). Furthermore, addition of a second DI resulted in increased risks of infection, hospitalization and, presumably, medical costs. 6 The issue of risks vs benefits of treatment intensification is not unique to CCG ALL studies. Therefore, a critical question to ask is whether all major subgroups of patients benefit from a specific intensification that results in real, but modest, overall improvements in EFS, or whether subgroups can be identified who might fare as well without further intensification.
Two biological features are present in substantial proportions of children with SR-ALL and have been associated consistently with an excellent treatment outcome. Hyperdiploid blast cell DNA content (DNA index у1.16) is present in 20-25% of children with SR-ALL and has been associated with EFS rates of 80-90% using contemporary chemotherapy regimens.
1,2,8-10 TEL-AML1 fusion, which results from a cryptic t (12;21) , is present in the leukemic blasts of 20-30% of children with SR-ALL. 3, [11] [12] [13] Numerous recent studies have demonstrated that children with TEL-AML1 fusion have EFS rates of 85-90%. 3, [14] [15] [16] As TEL-AML1 fusion and hyperdiploidy are almost completely mutually exclusive, one or the other is present in almost half of children with SR-ALL. To begin to explore the necessity of further treatment intensification for TEL-AML1-positive or hyperdiploid SR-ALL patients, we retrospectively analyzed outcome for children treated with CCG-based SDI therapy at The Children's Hospital, Denver, CO between 1983 and 1993. Our results provide a strong impetus to examine closely the effects of treatment intensification on specific subgroups of children with SR-ALL.
Materials and methods

Patient samples
DI was introduced into CCG therapies in 1983. To ensure a minimum of 5 years of follow-up, analyses were confined to patients diagnosed prior to July 1993. Between 5/1/83 and 7/1/93, 347 children with newly diagnosed ALL were treated at The Children's Hospital, Denver, Colorado. Records were reviewed, and patients were retrospectively classified as high or standard risk based on the NCI criteria. 7 Of these 347 patients, 218 were standard risk, 113 were high risk, five were infants less than 12 months of age, and 11 could not be classified because of missing data. Seventy-five of the standard risk patients received therapy 5 that included one DI and met the criteria for this study. Thirty-seven patients were enrolled in CCG studies and (randomly or non-randomly) assigned to SDI treatment. Thirty-eight patients were not enrolled in a CCG study, but received CCG-type therapy that included a single DI. The primary reasons for non-enrollment were that a CCG study was not open at the time the patient was diagnosed, or because the patient's parents did not consent to enrollment in an open trial. One hundred and thirty-five of the standard risk patients received therapy that included no or two DI phases, and eight patients were enrolled in non-CCG studies. We queried the database for the leukemia cell bank of The Children's Hospital and found that cryopreserved diagnostic specimens were available from 43 of the 75 patients treated with a SDI. Of these 43 patients, 21 were enrolled in a CCG trial and received SDI therapy and 22 were not enrolled in a CCG trial but were treated with SDI therapy. Clinical status given is current as of 1 October 1998. The current retrospective analyses were approved by the Institutional Review Board of the University of Colorado Health Sciences Center and The Children's Hospital.
Molecular analyses
TEL-AML1 fusion was identified using a nested reverse transcriptase-polymerase chain reaction (RT-PCR). Briefly, total RNA was extracted from cryopreserved specimens with RNAzol B (TEL-TEST, Friendswood, TX, USA) and 1-2 g of total RNA was converted to cDNA with Superscript RT (Gibco BRL, Gaithersburg, MD, USA) and random hexamer primers in a 30 l reaction. In the first round PCR reaction, 12 l of the RT product was amplified using TEL sense and AML1 antisense oligomers (TL667 and 3HO) 17 in a 50 l reaction that included 50 pmol of each primer, 200 mm dNTPs, 50 mm KCl, 10 mm Tris-HCl pH 8.3, 1.5 mm MgCl 2 , 0.001% gelatin, 5% DMSO, and 1.25 units of AmpliTaq Gold polymerase (Perkin Elmer, Foster City, CA, USA). Amplifications were performed in a GeneAmp PCR 9700 thermocycler for 40 cycles with an annealing temperature of 61°C. A second round of amplification was performed under identical conditions using 1 l of the first round PCR product and TEL sense and AML1 antisense oligomers TL841 and 3HI. 17 RNA from the REH and K562 cell lines was used as positive and negative controls, respectively. To confirm the integrity of isolated RNA, a portion of the Abl cDNA was amplified using previously described primers. 18 Twenty microliter aliquots of the PCR products were electrophoresed in 3% agarose 3:1 high resolution blend (Amresco, Solon, OH, USA) gels stained with ethidium bromide. Gels were photographed with UVP Gel Documentation System GDS7500 (UVP, Upland, CA, USA). For some cases, we confirmed PCR results by Southern blot analysis for TEL gene rearrangements as previously described. 19 
Ploidy determination
Standard cytogenetic analyses were performed routinely at the time of initial diagnosis in the clinical cytogenetics lab using procedures described previously. 20 DNA content had been determined in the clinical laboratory at the time of initial diagnosis by flow cytometry for 21 of the 75 patients. Cytogenetic and flow cytomery results for the 75 study patients were reviewed. ALLs that had a clone with a modal chromosome number of у51 identified by cytogenetics and/or those with a DNA index of у1.16 were classified as high hyperdiploid and are referred to subsequently as hyperdiploid. Cases with a DNA index Ͻ1.16 were classified as non-hyperdiploid. For cases that lacked sufficient data to assign ploidy and had cryopreserved material available for analysis, we retrospectively performed flow cytometry to determine ploidy. Flow cytometry was also repeated for cases with sufficient cryopreserved material. To perform these analyses, cryopreserved specimens were slowly thawed to room temperature and a 1:1 mixture of RPMI media: fetal bovine serum (FBS) was added to the specimen over a period of 10 min. Diluted specimens were then centrifuged at 400 g for 10 min, washed with RPMI containing 10% FBS, and re-centrifuged. Cells were counted using a hemocytometer, and tubes containing 2 × 10 6 cells, consisting of sample alone, sample plus normal lymphocytes, and normal lymphocytes alone, were stained overnight with Krishan's stain (0.224 g NaCit 2 H 2 O, 9.22 mg propidium iodide, 2.0 ml 1% NP40, 2 mg RNase, boiled). 21 Flow cytometry was performed in the flow cytometry core laboratory of the Cancer Center of the University of Colorado Health Sciences Center.
Statistical analyses
EFS and overall survival (OS) of groups based on clinical or molecular parameters were compared by log rank test and tests of proportional difference were done using the Fisher exact test. Both procedures are available in the SAS statistical package. 22 The multivariate analyses were done using the Cox proportional hazards model in SAS PROC PHREG. 22 KaplanMeier curves were constructed for EFS and OS for patients with or without TEL-AML1 fusion.
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Results and discussion
Forty-three of the 75 patients (57%) with SR-ALL treated with SDI CCG-based therapy had cryopreserved diagnostic samples available for molecular analysis. Nineteen of these 43 children (44%) were found to express TEL-AML1 fusion transcripts by RT-PCR and 24 (56%) were TEL-AML1-negative. Southern blots to detect TEL rearrangements were performed in 10 of 43 cases, and all results were concordant (seven PCRpositive cases contained TEL rearrangements, and three PCRnegative cases were TEL-germline; data not shown).
Ploidy was determined for 56 of the 75 patients based on cytogenetic analyses performed at the time of initial diagnosis, and/or flow cytometry performed at initial diagnosis or at the time of the TEL-AML1 analyses. Fifteen cases (27%) were hyperdiploid and 41 (73%) were non-hyperdiploid. Ploidy was determined for 41 of the cases with known TEL-AML1 status. None of 19 ALLs with TEL-AML1 fusion were hyperdiploid, vs nine of 22 (41%) lacking TEL-AML1 fusion (P = 0.0017 by two-sided Fisher exact test).
We next examined the EFS and OS for subgroups of patients based on clinical and biological features (age, white blood count, TEL-AML1 status and ploidy) present at diagnosis (Table 1) . Of the 43 patients with known TEL-AML1 status, 29 remain alive in first remission and 14 patients have experienced one or more relapses, four of whom have died following relapse. The 7-year EFS was 81% for the 19 TEL-AML1-positive patients, vs 54% for the 24 TEL-AML1-negative patients (P = 0.0264 by log rank test; Figure 1a) . Overall survival at 7 years for TEL-AML1-positive patients was 100% vs 83% for TEL-AML1-negative patients (P = 0.0677 by log rank test; Figure 1b) . The three TEL-AML1-positive patients who relapsed are currently in second remission at 31, 67 and 68 months following relapse. Consistent with results of other studies, 16 relapses in TEL-AML1-positive patients tended to occur later (mean 50 months, median 39 months for three patients) than did relapses in TEL-AML1-negative patients (mean 25 months, median 25 months for 11 patients). Children with an initial WBC Ͼ10 000/mm 3 had a significantly better EFS than those with a WBC Ͼ10 000/mm 3 (P = 0.038). Multivariate analyses were performed using both TEL-AML1 status and WBC to predict survival. Neither was significant for OS, but TEL-AML1 status remained significant for EFS (P = 0.02) even when WBC was included in the model. In contrast, no difference in EFS or OS was seen based on ploidy status or age.
Rubnitz et al 16 recently reviewed data regarding the frequency of TEL-AML1 fusion in children with ALL and its effect on treatment outcome. The 44% incidence of TEL-AML1 observed in our series is higher than the 20-30% generally reported. This difference is likely accounted for by variation due to small sample size and selection bias, as our study was limited to children with SR-ALL. The overall results of our analysis may also be affected by the small sample size and the fact that TEL-AML1 status could be determined for only 57% of the identified study group. The outcome observed for TEL-AML1-positive patients in this study is consistent with that found in previous reports. 16 However, the 54% 7-year EFS of the TEL-AML1-negative patients seems rather low for patients with SR-ALL. There are no obvious explanations for this potential discrepancy. Only one of the TEL-AML1-negative patients had a cytogenetic abnormality detected that has been associated with an adverse prognosis, an 8-year-old girl with a bal- anced t(1;19)(q23;p13) and E2A-PBX1 fusion. 24 This patient had a bone marrow relapse 10 months following diagnosis, underwent a bone marrow transplant in second remission, had a second marrow relapse within 90 days of the transplant, and died of progressive disease.
The current study is the first, to our knowledge, that has reported the effect of TEL-AML1 fusion on outcome of children with SR-ALL treated with 'CCG-type' therapy. While the DI phase used by the CCG was originally based on the BFM 76/79 study, the treatment received by our patients differed significantly from that given to patients treated in the ALL-BFM 90 and ALL-AIEOP 91 studies which Borkhardt et al 15 )-dose methotrexate, neither of which was received by the patients in our study. The European patients also received more intensive asparaginase therapy than was administered to our patients.
In contrast to findings of other investigators, [8] [9] [10] we did not observe any suggestion of an improved outcome in children with hyperdiploid SR-ALL, as compared to non-hyperdiploid SR-ALL, treated with therapy that included a SDI. This may be a function of limited power to detect differences due to small sample size, longer follow-up in our study than many of the other studies, or may be related to the specific chemotherapy administered to our patients.
We believe that these results, in conjunction with those reported previously by other investigators, provide a strong impetus to examine closely the effects of treatment intensification in specific subgroups of children with SR-ALL. In particular, it is critical to know whether well-defined subgroups that account for substantial proportions of SR-ALL patients, such as those with TEL-AML1 fusion or a hyperdiploid DNA content, benefit from further treatment intensification. While retrospective studies can provide useful starting information, this important question can only be answered definitively by prospective analyses performed in the context of large cooperative group trials.
Figure 1
Comparison of treatment outcome by TEL-AML1 status. Event-free (a) and overall (b) survival are shown for TEL-AML1-negative (solid lines) and -positive (dashed lines) patients. The data were analyzed by the Kaplan-Meier method and differences compared by the logrank test (P values given in Table 1 ).
Fellowship Award from the National Childhood Cancer Foundation and was also supported by a University of Colorado Cancer Center seed grant. SPH is supported by a Professional Development Award from The Children's Hospital Research Institute, Denver, CO and is a Leukemia Society of America Translational Research Awardee. This research was supported by a grant from the Children's Cancer Research Fund (CCRF) and a Cancer Center Core Grant (CA 46934). The contents of this publication do not necessarily represent the policies or views of the CCRF.
